NID1 and acute myeloid leukemia: Therefore, the association with KMT2A rearrangements and the absent expression in HSC emphasizes that NID1 could serve as an interesting biomarker and help us to further map this aggressive cell population and establish potential therapeutic strategies tackling the high relapse rates in AML patients.